Since the discovery of insulin in 1921 there has been little good news for the diabetic patient. The increase in our understanding of the metabolic abnormalities has not been successfully transplanted into meaningful advances in therapy. Insulin itself has failed to fulfill its early promise as a "cure" for diabetes. We now appreciate that although insulin prevents death and improves the well-being of patients with diabetes, its use is associated with the eventual development of vascular damage. Numerous systems of insulin delivery have been introduced in an effort to alter the course of diabetic vascular disease. Even so, more diabetics develop blindness, manifest coronary artery disease, and enter dialysis programs every year. At the present time none of the methods used to treat diabetes mellitus delivers insulin physiologically, i.e. into the hepatic portal circulation. The normal nondiabetic secretes insulin into the portal circulation, where the major portion acts on the liver, is extracted by it, and never gains entry to the systemic circulation (1). The present modes of insulin delivery, by contrast, produce insulin levels that are unphysiologically high in the systemic circulation but often subnormal in hepatic portal circulation (2, 3) . This systemic hyperinsulinemia and relative inadequacy of hepatic insulinization could be responsible for the microvascular and macrovascular problems seen in diabetic patients.
There is considerable evidence that insulin is atherogenic. This has been demonstrated in rabbits (4), chicken (5) and in isolated perfused arteries of experimentally-induced diabetes in dogs (6) . Humans studies have also shown strong correlation between atherosclerotic disease such as coronary artery disease and high fasting insulin levels (7) .
With regard to diabetic small vessel disease, the concept was advanced in the early '30s that high blood glucose concentration was responsible for diabetic retinopathy and other forms of small blood vessel disease. In the United States, the Joslin Clinic as well as other groups emphasized rigid control of blood glucose as a means of preventing of retarding diabetic microangiopathy. Despite high hopes for this approach, the 1971 review by Bondy and Felig (8) concluded that rigid blood glucose control probably did not alter the progression of diabetic microvascular disease. With the introduction of continuous subcutaneous insulin pump therapy (CSII) and sophisticated methods of self-monitoring of blood glucose concentrations, several studies were undertaken to compare the effects of rigid to conventional blood glucose control. Some of these studies, such as the Job study (9) and the initial Steno study (10) . were interpreted as showing less retinopathy with rigid control. However, as results became available from ongoing studies of the Steno group (11) as well as others conducting similar studies (12, 13) , it became apparent that rigidly controlled diabetics actually could develop accelerated retinal disease shortly after such control was imposed. The implications from these subsequent studies are that insulin itself may be responsible for microvascular disease. Support for this concept comes from the study of another unusual type(s) of diabetes mellitus generally referred to as maturity onset diabetes of the young (MODY) (14) . Patients in this group are heterogenous (15) but share the characteristics of high glucose concentration with near normal insulin concentrations. Although this profile may be present for decades, these patients are particularly resistant to the development of diabetic retinal disease (14) . This suggests that a high serum glucose concentration in the absence of high insulin levels is not particularly damaging to the small blood vessels.
It has been well established that kidney disease occurs in over 90% of diabetic patients (16) . However, only a third of these patients progress to develop clinical renal disease. Although a few studies reported limitation of renal damage from rigid glucose control (17) , others (18) failed to support this and the case for rigid glucose control in preventing diabetic nephropathy is unconvincing (19) . It is plausible, Oral insulin therapy however, that glomerular hyperfiltration and glomerular "hypertension" causes microalbuminuria and subsequent mesangial proliferation and sclerosis (20) . Although factors such as glucagon, growth hormone, ketones and glucose itself are known to increase glomerular filtration, it is speculated that the glomerular hyperfiltration may also be induced by altered hepatic production of vasoactive substances that normally regulate renal blood flow. One such substance, glomerulopressin, a low molecular weight glucuronide, has been shown to increase renal blood flow (21) . Since insulin tends to decrease the production of glomerulopressin when given into the portal circulation (22) , it is conceivable that the low portal concentrations of insulin that occur with present-day insulin regimens would not prevent glomerular hypertension despite adequate blood glucose control. The nephropathy in the type I diabetic is much quicker to develop than in the type II diabetic. Since the classic type I diabetic secretes virtually no insulin into the portal circulation, this would suggest that proper insulinization of the liver could prevent or retard diabetic nephropathy.
At present no method of insulin delivery can mimic the physiological secretion of insulin. Pancreatic grafts are generally not drained into the portal circulation. The Roux-in-Y technique that we used 15 years ago (23) would allow the venous drainage of the pancreas to be diverted into the portal vein and might arrest retinal and renal vascular disease in diabetic patients. Attempts to transplant islet tissue continue (24) and this approach may someday result in widely successful drainage of insulin into the hepatic portal circulation and thereby re-establish physiologic insulin secretion. Another approach towards re-establishing physiological effects of insulin on the liver consists of administering insulin by the oral route. Saffran has successfully delivered insulin coated with an azoaromatic copolymer (25) into the colon of dogs; and we have accomplished the same thing in humans using a methacrylic acid copolymer that dissolves only in the pH range found in the colon (26) . Such delivery of insulin into the portal circulation via oral administration in appropriately coated capsules might offer the most practical attempt to prevent diabetic microangiopathy and renaf disease, and to curtail insulin-induced atherosclerosis that occurs with the hyperinsulinemia associated with currently used insulin regimens. 
